Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2008

Open Access 01-12-2008 | Review

PTTG: an important target gene for ovarian cancer therapy

Authors: Siva Kumar Panguluri, Casey Yeakel, Sham S Kakar

Published in: Journal of Ovarian Research | Issue 1/2008

Login to get access

Abstract

Pituitary tumor transforming gene (PTTG), also known as securin is an important gene involved in many biological functions including inhibition of sister chromatid separation, DNA repair, organ development, and expression and secretion of angiogenic and metastatic factors. Proliferating cancer cells and most tumors express high levels of PTTG. Overexpression of PTTG in vitro induces cellular transformation and development of tumors in nude mice. The PTTG expression levels have been correlated with tumor progression, invasion, and metastasis. Recent studies show that down regulation of PTTG in tumor cell lines and tumors in vivo results in suppression of tumor growth, suggesting its important role in tumorigenesis. In this review, we focus on PTTG structure, sub-cellular distribution, cellular functions, and role in tumor progression with suggestions on possible exploration of this gene for cancer therapy.
Appendix
Available only for authorised users
Literature
1.
Bristol-Gould SK, Hutten CG, Sturgis C, Kilen SM, Mayo KE, Woodruff TK: The development of a mouse model of ovarian endosalpingiosis. Endocrinology 2005, 146: 5228–36. 10.1210/en.2005-0697PubMedCrossRef
2.
Bachelier R, Xu X, Li C, Qiao W, Furth PA, Lubet RA, Deng CX: Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. Oncol Rep 2005, 14: 1117–20.PubMed
3.
Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK: Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006, 66: 2527–31. 10.1158/0008-5472.CAN-05-4063PubMedCrossRef
4.
Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR: RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007, 67: 2408–13. 10.1158/0008-5472.CAN-06-4490PubMedCrossRef
5.
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC: Magnetic Resonance Imaging for Detection and Determination of Tumor Volume in a Genetically Engineered Mouse Model of Ovarian Cancer. Cancer Biol Ther 2007, 6: 1717–1725.PubMedCrossRef
6.
El-Naggar SM, Malik MT, Martin A, Moore JP, Proctor M, Hamid T, Kakar SS: Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice. J Endocrinol 2007, 194: 179–91. 10.1677/JOE-06-0036PubMedCrossRef
7.
Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997, 11: 433–441. 10.1210/me.11.4.433PubMedCrossRef
8.
Pei L: Genomic organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene. J Biol Chem 1998, 273: 5219–5225. 10.1074/jbc.273.9.5219PubMedCrossRef
9.
Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, Pintor-Toro JA: hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 1998, 17: 2187–2193. 10.1038/sj.onc.1202140PubMedCrossRef
10.
Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999, 285: 418–422. 10.1126/science.285.5426.418PubMedCrossRef
11.
Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999, 84: 761–767. 10.1210/jc.84.2.761PubMedCrossRef
12.
Kakar SS, Jennes L: Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet Cell Genet 1999, 84: 211–6. 10.1159/000015261PubMedCrossRef
13.
Heaney AP, Nelson V, Fernando M, Horwitz G: Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab 2001, 86: 5025–32. 10.1210/jc.86.10.5025PubMedCrossRef
14.
Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M: PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 2004, 13: 80–81. 10.1016/j.breast.2003.09.008PubMedCrossRef
15.
Puri R, Tousson A, Chen L, Kakar SS: Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett 2001, 163: 131–139. 10.1016/S0304-3835(00)00688-1PubMedCrossRef
16.
Tsai SJ, Lin SJ, Cheng YM, Chen HM, Wing LY: Expression and functional analysis of pituitary tumor transforming gene-1 [corrected] in uterine leiomyomas. J Clin Endocrinol Metab 2005, 90: 3715–3723. 10.1210/jc.2004-2303PubMedCrossRef
17.
Chamaon K, Kirches E, Kanakis D, Braeuninger S, Dietzmann K, Mawrin C: Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochem Biophys Res Commun 2005, 331: 86–92. 10.1016/j.bbrc.2005.03.124PubMedCrossRef
18.
Kakar SS, Malik MT: Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol 2006, 29: 387–395.PubMed
19.
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S: Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000, 26: 716–9. 10.1016/S0140-6736(99)10238-1CrossRef
20.
Lee IA, Seong C, Choe IS: Cloning and expression of human cDNA encoding human homologue of pituitary tumor transforming gene. Biochem Mol Biol Int 1999, 47: 891–897.PubMed
21.
Kakar SS: Assignment of the human tumor transforming gene TUTR1 to chromosome band 5q35.1 by fluorescence in situ hybridization. Cytogenet Cell Genet 1998,83(1–2):93–95. 10.1159/000015139PubMedCrossRef
22.
Kakar SS: Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG). Gene 1999, 240: 317–324. 10.1016/S0378-1119(99)00446-1PubMedCrossRef
23.
Chien W, Pei L: A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. J Biol Chem 2000, 275: 19422–19427. 10.1074/jbc.M910105199PubMedCrossRef
24.
Chen L, Puri R, Lefkowitz EJ, Kakar SS: Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization. Gene 2000, 248: 41–50. 10.1016/S0378-1119(00)00096-2PubMedCrossRef
25.
Saez C, Japon MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA: hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 1999, 18: 5473–5476. 10.1038/sj.onc.1202914PubMedCrossRef
26.
Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S: Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol 2000, 14: 1137–1146. 10.1210/me.14.8.1137PubMedCrossRef
27.
Stratford AL, Boelaert K, Tannahill LA, Kim DS, Warfield A, Eggo MC, Gittoes NJ, Young LS, Franklyn JA, McCabe CJ: Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab 2005, 90: 4341–4349. 10.1210/jc.2005-0523PubMedCrossRef
28.
Mu YM, Oba K, Yanase T, Ito T, Ashida K, Goto K, Morinaga H, Ikuyama S, Takayanagi R, Nawata H: Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1). Endocr J 2003, 50: 771–781. 10.1507/endocrj.50.771PubMedCrossRef
29.
Yaspo ML, Aaltonen J, Horelli-Kuitunen N, Peltonen L, Lehrach H: Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. Genomics 1998, 49: 133–6. 10.1006/geno.1998.5217PubMedCrossRef
30.
Uhlmann F, Lottspeich F, Nasmyth K: Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1. Nature 1999, 400: 37–42. 10.1038/21831PubMedCrossRef
31.
Waizenegger IC, Hauf S, Meinke A, Peters JM: Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase. Cell 2000, 103: 399–410. 10.1016/S0092-8674(00)00132-XPubMedCrossRef
32.
Michaelis C, Ciosk R, Nasmyth K: Cohesins: chromosomal proteins that prevent premature separation of sister chromatids. Cell 1997, 91: 35–45. 10.1016/S0092-8674(01)80007-6PubMedCrossRef
33.
King RW, Peters JM, Tugendreich S, Rolfe M, Hieter P, Kirschner MW: A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 1995, 81: 279–288. 10.1016/0092-8674(95)90338-0PubMedCrossRef
34.
Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, Ruderman JV, Hershko A: The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995, 6: 185–97.PubMedCentralPubMedCrossRef
35.
Cohen-Fix O, Peters JM, Kirschner MW, Koshland D: Anaphase initiation in Saccharomyces cerevisiae is controlled by the APC-dependent degradation of the anaphase inhibitor Pds1p. Genes Dev 1996, 10: 3081–3093. 10.1101/gad.10.24.3081PubMedCrossRef
36.
Funabiki H, Yamano H, Kumada K, Nagao K, Hunt T, Yanagida M: Cut2 proteolysis required for sister-chromatid seperation in fission yeast. Nature 1996, 381: 438–41. 10.1038/381438a0PubMedCrossRef
37.
Leismann O, Herzig A, Heidmann S, Lehner C: Degradation of Drosophila PIM regulates sister chromatid separation during mitosis. Genes Dev 2000, 14: 2192–2205. 10.1101/gad.176700PubMedCentralPubMedCrossRef
38.
Morgan D: Regulation of the APC and the exit from mitosis. Nature Cell Biol 1999, 1: E47-E53. 10.1038/10039PubMedCrossRef
39.
Zachariae W, Nasmyth K: Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev 1999, 13: 2039–2058. 10.1101/gad.13.16.2039PubMedCrossRef
40.
Amon A, Irniger S, Nasmyth K: Closing the cell cycle circle in yeast: G 2 cyclin proteolysis initiated at mitosis persists until the activation of G 1 cyclins in the next cycle. Cell 1994, 77: 1037–1050. 10.1016/0092-8674(94)90443-XPubMedCrossRef
41.
Brandeis M, Hunt T: The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of Sphase. EMBO J 1996, 15: 5280–5289.PubMedCentralPubMed
42.
Inbal N, Listovsky T, Brandeis M: The mammalian Fizzy and Fizzy-related genes are regulated at the transcriptional and post-transcriptional levels. FEBS Lett 1999, 463: 350–354. 10.1016/S0014-5793(99)01640-3PubMedCrossRef
43.
Funabiki H, Kumada K, Yanagida M: Fission yeast Cut1 and Cut2 are essential for sister chromatid separation, concentrate along the metaphase spindle and form large complexes. EMBO J 1996, 15: 6617–28.PubMedCentralPubMed
44.
Stratmann R, Lehner CF: Separation of sister chromatids in mitosis requires the Drosophila pimples product, a protein degraded after the metaphase/anaphase transition. Cell 1996, 84: 25–35. 10.1016/S0092-8674(00)80990-3PubMedCrossRef
45.
Ciosk R, Zachariae W, Michaelis C, Shevchenko A, Mann M, Nasmyth K: An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast. Cell 1998, 93: 1067–1076. 10.1016/S0092-8674(00)81211-8PubMedCrossRef
46.
Kinzler KW, Vogelstein B: Lessons from hereditary colon cancer. Cell 1996, 87: 159–170. 10.1016/S0092-8674(00)81333-1PubMedCrossRef
47.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998, 396: 643–649. 10.1038/25292PubMedCrossRef
48.
Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, Peters JM, Kinzler KW, Vogelstein B, Lengauer C: Securin is required for chromosomal stability in human cells. Cell 2001, 105: 445–457. 10.1016/S0092-8674(01)00340-3PubMedCrossRef
49.
Wang Z, Yu R, Melmed S: Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 2001, 15: 1870–1879. 10.1210/me.15.11.1870PubMedCrossRef
50.
Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, Pintor-Toro JA, Tortolero M: Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res 2001, 29: 1300–1307. 10.1093/nar/29.6.1300PubMedCentralPubMedCrossRef
51.
Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X: DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem 2003, 278: 462–470. 10.1074/jbc.M203793200PubMedCrossRef
52.
Pei L: Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells. J Biol Chem 1999, 274: 3151–3158. 10.1074/jbc.274.5.3151PubMedCrossRef
53.
Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, Tortolero M: Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 2000, 19: 403–409. 10.1038/sj.onc.1203320PubMedCrossRef
54.
Pei L: Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 2001, 276: 8484–8491. 10.1074/jbc.M009654200PubMedCrossRef
55.
Boelaert K, Tannahill LA, Bulmer JN, Kachilele S, Chan SY, Kim D, Gittoes NJ, Franklyn JA, Kilby MD, McCabe CJ: A potential role for PTTG/securin in the developing human fetal brain. FASEB J 2003, 17: 1631–1639. 10.1096/fj.02-0948comPubMedCrossRef
56.
Saez C, Martinez-Brocca MA, Castilla C, Soto A, Navarro E, Tortolero M, Pintor-Toro JA, Japon MA: Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab 2006, 91: 1404–1409. 10.1210/jc.2005-2532PubMedCrossRef
57.
Jin S, Weaver DT: Double-strand break repair by Ku70 requires heterodimerization with Ku80 and DNA binding functions. EMBO J 1997, 16: 6874–6885. 10.1093/emboj/16.22.6874PubMedCentralPubMedCrossRef
58.
Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B: Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 1998, 17: 5085–94. 10.1093/emboj/17.17.5085PubMedCentralPubMedCrossRef
59.
Thompson AD 3rd, Kakar SS: Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett 2005, 579: 3195–200. 10.1016/j.febslet.2005.05.008PubMedCrossRef
60.
Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S: Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 1999, 5: 1317–1321. 10.1038/15275PubMedCrossRef
61.
Tfelt-Hansen J, Yano S, Bandyopadhyay S, Carroll R, Brown EM, Chattopadhyay N: Expression of pituitary tumor transforming gene (PTTG) and its binding protein in human astrocytes and astrocytoma cells: function and regulation of PTTG in U87 astrocytoma cells. Endocrinology 2004, 145: 4222–4231. 10.1210/en.2003-1661PubMedCrossRef
62.
Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, Melmed S: Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Mol Endocrinol 2006, 20: 3321–3335. 10.1210/me.2006-0280PubMedCrossRef
63.
Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Ishiguro H, Kudo J, Terashita Y, Konishi S, Fujii Y: Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 2002, 32: 233–237. 10.1093/jjco/hyf058PubMedCrossRef
64.
Honda S, Hayashi M, Kobayashi Y, Ishikawa Y, Nakagawa K, Tsuchiya E: A role for the pituitary tumor-transforming gene in the genesis and progression of non-small cell lung carcinomas. Anticancer Res 2003, 23: 3775–3782.PubMed
65.
Rehfeld N, Geddert H, Atamna A, Rohrbeck A, Garcia G, Kliszewski S, Neukirchen J, Bruns I, Steidl U, Fenk R, Gabbert HE, Kronenwett R, Haas R, Rohr UP: The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog 2006, 5: 4. 10.1186/1477-3163-5-4PubMedCentralPubMedCrossRef
66.
Tfelt-Hansen J, Schwarz P, Terwilliger EF, Brown EM, Chattopadhyay N: Calcium-sensing receptor induces messenger ribonucleic acid of human securin, pituitary tumor transforming gene, in rat testicular cancer. Endocrinology 2003, 144: 5188–5193. 10.1210/en.2003-0520PubMedCrossRef
67.
Chen G, Li J, Li F, Li X, Zhou J, Lu Y, Ma D: Inhibitory effects of anti-sense PTTG on malignant phenotype of human ovarian carcinoma cell line SK-OV-3. J Huazhong Univ Sci Technolog Med Sci 2004, 24: 369–372.PubMedCrossRef
68.
Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS: Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo . Hepatology 2006, 43: 1042–1052. 10.1002/hep.21137PubMedCrossRef
69.
Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, Watkinson JC, Ishmail T, Wakelam MJ, McCabe CJ: Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 2007, 28: 749–59. 10.1093/carcin/bgl202PubMedCrossRef
70.
71.
Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S: Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab 2001, 86: 867–874. 10.1210/jc.86.2.867PubMed
72.
Kim DS, Buchanan MA, Stratford AL, Watkinson JC, Eggo MC, Franklyn JA, McCabe CJ: PTTG promotes a novel VEGF-KDR-ID3 autocrine mitogenic pathway in thyroid cancer. Clin Otolaryngol 2006, 31: 246. 10.1111/j.1749-4486.2006.01236_6.xCrossRef
73.
Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R: Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401: 670–677. 10.1038/44334PubMedCrossRef
74.
Lasorella A, Uo T, Iavarone A: Id proteins at the cross-road of development and cancer. Oncogene 2001, 20: 8326–8333. 10.1038/sj.onc.1205093PubMedCrossRef
75.
Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7: 1194–1201. 10.1038/nm1101-1194PubMedCrossRef
76.
McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ: Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002, 87: 4238–4244. 10.1210/jc.2002-020309PubMedCrossRef
77.
Boelaert K, Yu R, Tannahill LA, Stratford AL, Khanim FL, Eggo MC, Moore S, Young LC, Gittoes NJ, Franklyn JA, Melmed S, McCabe CJ: PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. J Mol Endocrinol 2004, 33: 663–677. 10.1677/jme.1.01606PubMedCrossRef
78.
Solbach C, Roller M, Eckerdt F, Peters S, Knecht R: Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer 2006,9(6):242. 10.1186/1471-2407-6-242CrossRef
79.
Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nature Genetics 2003, 33: 49–54. 10.1038/ng1060PubMedCrossRef
80.
Malik MT, Kakar SS: Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer 2006, 5: 61. 10.1186/1476-4598-5-61PubMedCentralPubMedCrossRef
81.
Toi M, Ishigaki S, Tominaga T: Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 1998, 52: 113–124. 10.1023/A:1006167202856PubMedCrossRef
82.
Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell CL, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995, 6: 387–400.PubMedCentralPubMedCrossRef
83.
Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI: Effects of p21Cip1/Waf1 at both the G1/S and the G2/M Cell Cycle Transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998, 18: 629–643.PubMedCentralPubMedCrossRef
84.
Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994, 54: 3391–3395.PubMed
85.
Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995, 92: 5545–5549. 10.1073/pnas.92.12.5545PubMedCentralPubMedCrossRef
86.
Datto MB, Yu Y, Wang XF: Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 1995, 270: 28623–28628. 10.1074/jbc.270.48.28623PubMedCrossRef
87.
Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, Wawrowsky K, Melmed S: Early multipotential pituitary focal hyperplasia in the α-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 2005, 19: 1383–1391. 10.1210/me.2004-0403PubMedCrossRef
88.
Matzuk MM, DeMayo FJ, Hadsell LA, Kumar TR: Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice. Biol Reprod 2003, 69: 338–346. 10.1095/biolreprod.102.013953PubMedCrossRef
89.
Rulli SB, Ahtiainen P, Makela S, Toppari J, Poutanen M, Huhtaniemi I: Elevated steroidogenesis, defective reproductive organs, and infertility in transgenic male mice overexpressing human chorionic gonadotropin. Endocrinology 2003, 144: 4980–4990. 10.1210/en.2003-0403PubMedCrossRef
90.
Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S: Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol 2005, 19: 2371–2379. 10.1210/me.2005-0137PubMedCentralPubMedCrossRef
91.
Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 1992, 359: 295–300. 10.1038/359295a0PubMedCrossRef
92.
Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY: Heterozygous Rb-1 δ 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994, 9: 1021–1027.PubMed
93.
Classon M, Harlow E: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002, 2: 910–917. 10.1038/nrc950PubMedCrossRef
94.
Wang Z, Yu R, Melmed S: Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 2001, 15: 1870–1879. 10.1210/me.15.11.1870PubMedCrossRef
95.
Wang Z, Moro E, Kovacs K, Yu R, Melmed S: Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic β-cell proliferation and diabetes. Proc Natl Acad Sci USA 2003, 100: 3428–3432. 10.1073/pnas.0638052100PubMedCentralPubMedCrossRef
96.
97.
Kakar SS, Leilei Chen L, Rashmi Puri R, Shawn E, Flynn SE, Lothar Jennes L: Characterization of a Polyclonal Antibody to Human Pituitary Tumor Transforming Gene 1 (PTTG1) Protein. J Histochem Cytochem 2001, 49: 1537–1546.PubMedCrossRef
98.
99.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806–11. 10.1038/35888PubMedCrossRef
100.
El-Naggar SM, Malik MT, Kakar SS: Small interfering RNA against PTTG: a novel therapy for ovarian cancer. Int J Oncol 2007, 31: 137–43.PubMed
101.
Kay MA, Glorioso JC, Naldini L: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001, 7: 33–40. 10.1038/83324PubMedCrossRef
102.
Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4: 346–358. 10.1038/nrg1066PubMedCrossRef
103.
Edelstein ML, Abedi MR, Wixon J, Edelstein RM: Gene therapy clinical trials worldwide 1989–2004-an overview. J Gene Med 2004, 6: 597–602. 10.1002/jgm.619PubMedCrossRef
104.
Metadata
Title
PTTG: an important target gene for ovarian cancer therapy
Authors
Siva Kumar Panguluri
Casey Yeakel
Sham S Kakar
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2008
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/1757-2215-1-6

Other articles of this Issue 1/2008

Journal of Ovarian Research 1/2008 Go to the issue

Editorial

Welcome to Journal of Ovarian Research

Review

Ovarian cancer: emerging concept on cancer stem cells

Research

Ovarian hyperstimulation syndrome and prophylactic human embryo cryopreservation: analysis of reproductive outcome following thawed embryo transfer

Review

Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype

Research

Functional significance of the signal transduction pathways Akt and Erk in ovarian follicles: in vitro and in vivo studies in cattle and sheep

Research

Can subjective global assessment of nutritional status predict survival in ovarian cancer?